If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Mounjaro™ (tirzepatide) injection2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Tirzepatide: Use in Patients With Gastroparesis
Tirzepatide has not been studied in people with delayed gastric emptying.
There is no information on the use of tirzepatide in people with gastroparesis because patients were excluded from tirzepatide clinical trials if they had a known clinically significant gastric emptying abnormality (for example, severe diabetic gastroparesis or gastric outlet obstruction).
Date of Last Review: February 05, 2021